IP Library › Granted Patent US 12,240,902

Granted Patent B2

US 12,240,902 · App. 17/402,986 · Granted Mar 4, 2025

Anti-TREM2 antibodies and methods of use thereof

Inventors: Mark S. Dennis (South San Francisco, CA); Sherie Duncan (South San Francisco, CA); Kathleen Lisaingo (South San Francisco, CA); Kathryn M. Monroe (South San Francisco, CA); Joshua I. Park (South San Francisco, CA); Rachel Prorok (South San Francisco, CA); Ju Shi (South San Francisco, CA); Ankita Srivastava (South San Francisco, CA); Bettina Van Lengerich (South San Francisco, CA); Riley Walsh (South San Francisco, CA)

Assignee: Denali Therapeutics Inc.

C07K16/2803 A61K2039/505 C07K2317/24 C07K2317/565 C07K2317/75 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,240,902
App. No.: 17/402,986
Granted: Mar 4, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Claims (140)

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to a human triggering receptor expressed on myeloid cells 2 (TREM2), wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the sequence of G-Y-T-F-T-α6-Y-α8-α9-α10 (SEQ ID NO:293), wherein α6 is N, S, or D; α8 is W or N; α9 is I or M; and α10 is S, T, M, or H;

(b) a CDR-H2 sequence comprising the sequence of β1-I-β3-P-β5-β6-β7-β8-β9-β10-Y-N-β13-β14-F-β16-β17 (SEQ ID NO:294), wherein β1 is D or Y; β3 is Y or F; β5 is H, G, S, N, or β6 is S or N; β7 is T or G; β8 is S, N, or G; β9 is T or N; β10 is N or G; β13 is E or Q; β14 is R or K; β16 is R or K; and β17 is S, G, or N;

(c) a CDR-H3 sequence comprising the sequence of γ1-R-γ3-G-γ5-G-γ7-γ8-γ9 (SEQ ID NO:295), wherein γ1 is A or S; γ3 is E or S; γ5 is F, Y, R, or T; γ7 is I or F; γ8 is S or A; and γ9 is A or Y;

(d) a CDR-L1 sequence comprising:

(i) the sequence of δ1-A-δ3-δ4-δ5-V-δ7-δ8-Y-δ10-δ11 (SEQ ID NO:296), wherein δ1 is S or K; δ3 is T or S; δ4 is S or E; δ5 is S or N; δ7 is absent or G; δ8 is S or T; δ10 is M or V; and δ11 is H or S; or

(ii) the sequence of δ1-S-S-δ4-S-L-L-δ8-S-δ10-N-δ12-δ13-δ14-Y-L-δ17 (SEQ ID NO:297), wherein δ1 is K or R; δ4 is Q or K; δ8 is N or H; δ10 is G or absent; δ12 is Q or G; δ13 is K or N; δ14 is N or T; and δ17 is T or Y;

(e) a CDR-L2 sequence comprising the sequence of ε1-ε2-S-ε4-ε5-ε6-ε7 (SEQ ID NO:298), wherein ε1 is S, G, W or Q; ε2 is T, A, or M; ε4 is N or T; ε5 is L or R; ε6 is A, Y, or E; and ε7 is S or T; and

(f) a CDR-L3 sequence comprising the sequence of ϕ1-ϕ2-ϕ3-ϕ4-ϕ5-ϕ6-P-ϕ8-T (SEQ ID NO:299), wherein ϕ1 is Q, G, or M; ϕ2 is Q or N; ϕ3 is R, S, D, or H; ϕ4 is S, Y, or L; ϕ5 is S or Q; ϕ6 is Y or F; and ϕ8 is L, F, or Y.

2. The isolated antibody or antigen-binding fragment of claim 1 , wherein:

(a) the CDR-H1 sequence is selected from SEQ ID NOS:4, 12, 20, 28, and 36; and/or

(b) the CDR-H2 sequence is selected from SEQ ID NOS:5, 13, 21, 29, and 37; and/or

(d) the CDR-L1 sequence is selected from SEQ ID NOS:7, 15, 23, 31, and 39; and/or

(e) the CDR-L2 sequence is selected from SEQ ID NOS:8, 16, 24, 32, and 40; and/or

(f) the CDR-L3 sequence is selected from SEQ ID NOS:9, 17, 25, 33, and 41.

3. The isolated antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:28, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:31, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:33; or

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:39, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:40, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:41.

4. The isolated antibody or antigen-binding fragment of claim 1 , comprising:

(a) a heavy chain variable region (V H ) sequence that has at least 85% sequence identity to any one of SEQ ID NOS:2, 10, 18, 26, or 34; and/or

(b) a light chain variable region (V L ) sequence that has at least 85% sequence identity to any one of SEQ ID NOS:3, 11, 19, 27, or 35.

5. The isolated antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises:

(a) a V H sequence comprising SEQ ID NO:26 and a V L sequence comprising SEQ ID NO:27; or

(b) a V H sequence comprising SEQ ID NO:34 and a V L sequence comprising SEQ ID NO:35.

6. The isolated antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the sequence of G-Y-T-F-T-α 6 -Y-W-I-α 10 (SEQ ID NO:300), wherein α 6 is N or S; and α 10 is S, T or M;

(b) a CDR-H2 sequence comprising the sequence of D-I-Y-P-β 5 -S-β 7 -β 8 -T-N-Y-N-E-β 14 -F-β 16 -β 17 (SEQ ID NO:301), wherein β 5 is H, G, or S; β 7 is T or G; β 8 is S or N; β 14 is R or K; β 16 is R or K; and β 17 is S or N;

(c) a CDR-H3 sequence comprising the sequence of γ 1 -R-E-G-γ 5 -G-I-S-A (SEQ ID NO:302), wherein γ 1 is A or S; and γ 5 is F or Y;

(d) a CDR-L1 sequence comprising the sequence of δ 1 -A-δ 3 -δ 4 -δ 5 -V-δ 7 -δ 8 -Y-δ 10 -δ 11 (SEQ ID NO:296), wherein δ 1 is S or K; δ 3 is T or S; δ 4 is S or E; δ 5 is S or N; δ 7 is absent or G; δ 8 is S or T; δ 10 is M or V; and δ 11 is H or S;

(e) a CDR-L2 sequence comprising the sequence of ε 1 -ε 2 -S-N-ε 5 -ε 6 -ε 7 (SEQ ID NO:304), wherein ε 1 is S or G; ε 2 is T or A; ε 5 is L or R; ε 6 is A or Y; and ε 7 is S or T; and

(f) a CDR-L3 sequence comprising the sequence of ϕ 1 -Q-ϕ 3 -ϕ 4 -S-ϕ 6 -P-ϕ 8 -T (SEQ ID NO:305), wherein ϕ 1 is Q or G; ϕ 3 is R or S; ϕ 4 is S or Y; ϕ 6 is Y or F; and ϕ 8 is L or F.

7. The isolated antibody or antigen-binding fragment of claim 6 , wherein:

(a) the CDR-H1 sequence is selected from SEQ ID NOS:4, 12, and 20; and/or

(b) the CDR-H2 sequence is selected from SEQ ID NOS:5, 13, and 21; and/or

(d) the CDR-L1 sequence is selected from SEQ ID NOS:7, 15, and 23; and/or

(e) the CDR-L2 sequence is selected from SEQ ID NOS:8, 16, and 24; and/or

(f) the CDR-L3 sequence is selected from SEQ ID NOS:9, 17, and 25.

8. The isolated antibody or antigen-binding fragment of claim 6 , wherein the antibody or antigen-binding fragment comprises:

(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:6, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:7, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:9; or

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:12, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:13, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:14, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:15, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:16, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:17; or

(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:20, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:21, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:22, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:24, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:25.

9. The isolated antibody or antigen-binding fragment of claim 8 , wherein the antibody or antigen-binding fragment comprises:

(a) a V H sequence comprising SEQ ID NO:2 and a V L sequence comprising SEQ ID NO:3; or

(b) a V H sequence comprising SEQ ID NO: 10 and a V L sequence comprising SEQ ID NO:11; or

10. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

11. A method of treating a neurodegenerative disease in a subject, comprising administering to the subject the isolated antibody or antigen-binding fragment thereof of claim 1 .

12. The method of claim 11 , wherein the neurodegenerative disease is selected from the group consisting of: Alzheimer's disease, primary age-related tauopathy, progressive supranuclear palsy (PSP), frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, argyrophilic grain dementia, amyotrophic lateral sclerosis, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS-PDC), corticobasal degeneration, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, familial British dementia, familial Danish dementia, Gerstmann-Straussler-Scheinker disease, globular glial tauopathy, Guadeloupean parkinsonism with dementia, Guadelopean PSP, Hallevorden-Spatz disease, hereditary diffuse leukoencephalopathy with spheroids (HDLS), Huntington's disease, inclusion-body myositis, multiple system atrophy, myotonic dystrophy, Nasu-Hakola disease, neurofibrillary tangle-predominant dementia, Niemann-Pick disease type C, pallido-ponto-nigral degeneration, Parkinson's disease, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, subacute sclerosing panencephalitis, and tangle only dementia.

13. An isolated antibody or antigen-binding fragment thereof that specifically binds to a human TREM2, wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the sequence of G-Y-α 3 -F-α 5 -S-α 7 -α 8 -α 9 -α 10 (SEQ ID NO:306), wherein α 3 is S or K; α 5 is T or P; α 7 is Y or F; α 8 is L or I; α 9 is M or I; and α 10 is N or H;

(b) a CDR-H2 sequence comprising the sequence of Y-I-N-P-Y-S-β 7 -G-β 9 -N-Y-N-E-K-F-K-β 17 (SEQ ID NO:307), wherein β 7 is A or D; β 9 is S or T; and β 17 is D or G;

(d) a CDR-L1 sequence comprising the sequence of comprising the sequence of KASEDIYNRLA (SEQ ID NO:47);

(e) a CDR-L2 sequence comprising the sequence of comprising the sequence of GATSLET (SEQ ID NO:48); and

(f) a CDR-L3 sequence comprising the sequence of comprising the sequence Q-Q-ϕ 3 -W-S-ϕ 6 -P-W-T (SEQ ID NO:308), wherein ϕ 3 is Y or S; and ϕ 6 is T or I.

14. The isolated antibody or antigen-binding fragment of claim 13 , wherein the antibody or antigen-binding fragment comprises:

(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:49; or

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:52, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:292; or

(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:56, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:49.

15. An isolated antibody or antigen-binding fragment thereof that specifically binds to a human TREM2, wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the sequence of G-F-S-L-T-α 6 -Y-G-α 9 -α 10 (SEQ ID NO:310), wherein α 6 is T or S; α 9 is I or V; and α 10 is H or Q;

(b) a CDR-H2 sequence comprising the sequence of V-I-W-T-G-G-β 7 -T-β 9 -β 10 -N-A-A-F-M-S(SEQ ID NO:311), wherein β 7 is S or T; β 9 is A or D; and β 10 is F or Y;

(c) a CDR-H3 sequence comprising the sequence of A-K-γ 3 -G-F-H-S-A-γ 9 -D-Y (SEQ ID NO:312), wherein γ 3 is V or I; and γ 9 is T, M, or V;

(d) a CDR-L1 sequence comprising the sequence of R-S-S-Q-N-δ 6 -V-H-S-N-G-N-T-Y-L-E (SEQ ID NO:313), wherein δ 6 is L or I;

(e) a CDR-L2 sequence comprising the sequence of KVSNRFS (SEQ ID NO:89); and

(f) a CDR-L3 sequence comprising the sequence of F-Q-G-S-H-ϕ 6 -P-F-T (SEQ ID NO:314), wherein ϕ 6 is V or I.

16. The isolated antibody or antigen-binding fragment of claim 15 , wherein the antibody or antigen-binding fragment comprises:

(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:85, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:86, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:87, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:88, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:90; or

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:93, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:94, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:95, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:96, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:97; or

(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:101 a CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:96, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:90.

17. An isolated antibody or antigen-binding fragment thereof that specifically binds to a human TREM2, wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the sequence of GFTFTDYYMS (SEQ ID NO:125);

(b) a CDR-H2 sequence comprising the sequence of F-I-R-β 4 -K-A-N-G-Y-T-T-β 12 -Y-S-A-S-V-K-G (SEQ ID NO:320), wherein β 4 is N or D; and β 12 is E or D;

(c) a CDR-H3 sequence comprising the sequence of γ 1 -R-γ 3 -L-R-A-Q-G-F-A-Y (SEQ ID NO:321), wherein γ 1 is A or S; γ 3 is V or L;

(d) a CDR-L1 sequence comprising the sequence of δ 1 -S-δ 3 -Q-S-L-L-Y-S-δ 10 -N-Q-K-N-Y-L-A (SEQ ID NO:322), wherein δ 1 is T or K; δ 3 is G or S; and δ 10 is N or S;

(e) a CDR-L2 sequence comprising the sequence of WASTRES (SEQ ID NO:32); and

(f) a CDR-L3 sequence comprising the sequence of Q-Q-Y-Y-ϕ 5 -N-P-F-T (SEQ ID NO:323), wherein ϕ 5 is R or G.

18. The isolated antibody or antigen-binding fragment of claim 17 , wherein the antibody or antigen-binding fragment comprises:

(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:136, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:137, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:138, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:139; or

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:127, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:128, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:129; or

(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:132, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:127, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:128, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 133.

19. An isolated antibody or antigen-binding fragment thereof that specifically binds to a human TREM2, wherein the antibody or antigen-binding fragment thereof comprises:

(a) a CDR-H1 sequence comprising the amino acid sequence of any one of SEQ ID NOS:4, 12, 20, 28, 36, 44, 52, 56, 60, 68, 85, 93, 100, 105, 125, 142, 149, 157, 165, 172, 180, 188, 196, 202, 222, 228, 239, 253, 266, 274, and 282;

(b) a CDR-H2 sequence comprising the amino acid sequence of any one of SEQ ID NOS:5, 13, 21, 29, 37, 45, 53, 57, 61, 69, 81, 86, 94, 101, 106, 115, 117, 119, 126, 132, 136, 143, 150, 158, 166, 173, 181, 189, 197, 203, 209, 214, 217, 223, 229, 236, 240, 254, 267, 275, 283, and 289;

(c) a CDR-H3 sequence comprising the amino acid sequence of any one of SEQ ID NOS:6, 14, 22, 30, 38, 46, 62, 70, 73, 87, 95, 102, 107, 127, 137, 144, 151, 159, 167, 174, 182, 190, 198, 204, 210, 230, 241, 245, 249, 255, 260, 268, 276, and 284;

(d) a CDR-L1 sequence comprising the amino acid sequence of any one of SEQ ID NOS:7, 15, 23, 31, 39, 47, 63, 79, 88, 96, 108, 128, 138, 145, 152, 160, 168, 175, 183, 191, 199, 205, 218, 224, 231, 242, 246, 256, 261, 269, 277, and 285;

(e) a CDR-L2 sequence comprising the amino acid sequence of any one of SEQ ID NOS:8, 16, 24, 32, 40, 48, 64, 89, 109, 153, 161, 176, 184, 211, 219, 232, 250, 262, 270, 278, and 286; and

(f) a CDR-L3 sequence comprising the amino acid sequence of any one of SEQ ID NOS:9, 17, 25, 33, 41, 49, 65, 74, 90, 97, 110, 129, 133, 139, 146, 154, 162, 169, 177, 185, 193, 206, 212, 225, 233, 257, 263, 271, 279, 287, and 290.

20. The isolated antibody or antigen-binding fragment of claim 19 , wherein the antibody or antigen-binding fragment comprises:

(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:28, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:31, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:33; or

(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:36, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:37, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:38, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:39, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:40, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:41; or

(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:44, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:45, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:49; or

(g) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:61, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:62, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:65; or

(h) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:61, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:73, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:74; or

(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:61, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:73, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:79, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:74; or

(j) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:81, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:73, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:74; or

(k) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:81, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:73, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:79, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:74; or

(1) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:68, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:69, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:70, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:65; or

(m) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:85, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:86, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:87, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:88, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:90; or

(n) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:93, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:94, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:95, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:96, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:97; or

(o) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:100, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:101, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:102, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:96, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:90; or

(p) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:106, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:107, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:109, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:110; or

(q) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:115, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:107, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:109, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:110; or

(r) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:117, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:107, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:109, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:110; or

(s) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:105, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:119, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:107, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:108, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:109, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:110; or

(t) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:127, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:128, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 129; or

u) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:132, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:127, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:128, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:133; or

(v) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:125, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:136, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:137, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:138, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 139; or

(w) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:142, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:143, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:144, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:145, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:146; or

(x) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:149, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:150, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:151, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:152, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:153, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:154; or

(y) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:157, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:158, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:159, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:160, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:161, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:162; or

(z) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:165, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 166, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:167, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:168, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:161, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 169; or

(aa) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:172, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:173, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:174, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:175, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:176, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:177; or

(bb) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:180, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:181, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:182, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:183, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:184, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:185; or

(cc) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:188, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 189, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:190, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:191, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 146; or

(dd) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:188, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:189, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:190, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:191, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:193; or

(ee) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:196, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:197, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:198, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:199, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:90; or

(ff) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:202, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:203, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:204, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:205, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:206; or

(gg) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:28, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:209, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:210, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:205, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:211, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:212; or

(hh) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:172, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:214, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:174, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:175, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:176, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:177; or

(ii) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:149, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:217, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:167, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:218, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:219, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:169; or

(jj) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:222, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:223, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:22, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:224, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:8, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:225; or

(kk) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:228, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:229, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:230, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:231, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:232, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:233; or

(11) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:149, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:236, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:151, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:152, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:153, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:154; or

(mm) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:239, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:240, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:241, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:242, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:89, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:212; or

(nn) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:228, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:229, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:245, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:246, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:232, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:233; or

(oo) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:228, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:229, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:249, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:246, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:250, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:233; or

(pp) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:253, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:254, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:255, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:256, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:32, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:257; or

a CDR-H1 comprising the amino acid sequence of SEQ ID NO:253, a CDR-H2 (qq) comprising the amino acid sequence of SEQ ID NO:254, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:260, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:261, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:262, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:263; or

(rr) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:266, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:267, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:268, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:269, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:270, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:271; or

(ss) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:274, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:275, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:276, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:277, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:278, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:279; or

(tt) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:282, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:283, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:284, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:285, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:286, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:287; or

(uu) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:289, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:73, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:290; or

(vv) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:52, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:53, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:292; or

(ww) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:56, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:57, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:46, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:47, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:48, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:49.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022

From: DENNIS, MARK S.; MONROE, KATHRYN M.; PARK, JOSHUA I.; PROROK, RACHEL; SHI, JU; SRIVASTAVA, ANKITA; VAN LENGERICH, BETTINA

To: DENALI THERAPEUTICS INC.

Reel/Frame 059079/0114 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2022

From: DUNCAN, SHERIE; LISAINGO, KATHLEEN; WALSH, RILEY

To: ABCELLERA BIOLOGICS INC.

Reel/Frame 059010/0594 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2022

From: ABCELLERA BIOLOGICS INC.

To: DENALI THERAPEUTICS INC.

Reel/Frame 058977/0657 →

Continuity (3)

Continuation PCTUS2020019104 · Feb 20, 2020

Provisional Application 62808141 · Feb 20, 2019

Related Publication 20220119522A1 · Apr 21, 2022

References Cited (92)

US 8231878B2 · Colonna et al. · 2012 [cited by applicant]

US 8981061B2 · Colonna et al. · 2015 [cited by applicant]

US 9663587B2 · Hsieh et al. · 2017 [cited by applicant]

US 10457717B2 · Chen et al. · 2019 [cited by applicant]

US 10870837B2 · Henry et al. · 2020 [cited by applicant]

US 11124567B2 · Dennis et al. · 2021 [cited by applicant]

US 20170240631A1 · Monroe et al. · 2017 [cited by applicant]

US 20200216522A1 · Chen et al. · 2020 [cited by applicant]

US 20200223935A1 · Chen et al. · 2020 [cited by applicant]

US 20200262890A1 · Chen et al. · 2020 [cited by applicant]

US 20200277373A1 · Chen et al. · 2020 [cited by applicant]

US 20200289627A1 · Dennis et al. · 2020 [cited by applicant]

US 20200369746A1 · Chen et al. · 2020 [cited by applicant]

US 20210070881A1 · Dennis et al. · 2021 [cited by applicant]

US 20210130485A1 · Dennis et al. · 2021 [cited by applicant]

US 20210198640A1 · Astarita et al. · 2021 [cited by applicant]

US 20210284702A1 · Di Paolo et al. · 2021 [cited by applicant]

US 20220002436A1 · Dennis et al. · 2022 [cited by applicant]

US 20220017634A1 · Kannan et al. · 2022 [cited by applicant]

US 20220025039A1 · Astarita et al. · 2022 [cited by applicant]

US 20220025065A1 · Arguello et al. · 2022 [cited by applicant]

US 20220073609A1 · Dennis et al. · 2022 [cited by applicant]

US 20220177576A1 · Dennis et al. · 2022 [cited by applicant]

US 20220184186A1 · Andersen et al. · 2022 [cited by applicant]

US 20220213155A1 · Cherf et al. · 2022 [cited by applicant]

CN 105218669A · 2016 [cited by applicant]

KR 102156165B1 · 2020 [cited by applicant]

WO 2010079039A1 · 2010 [cited by applicant]

WO 2014178820A1 · 2014 [cited by applicant]

WO 2015033223A2 · 2015 [cited by applicant]

WO 2016023019A2 · 2016 [cited by applicant]

WO 2016049641A1 · 2016 [cited by applicant]

WO 2016156291A1 · 2016 [cited by applicant]

WO 2017058866A1 · 2017 [cited by applicant]

WO 2017062672A2 · 2017 [cited by applicant]

WO 2017147509A1 · 2017 [cited by applicant]

WO 2017189959A1 · 2017 [cited by applicant]

WO 2018015573A2 · 2018 [cited by applicant]

WO 2018119351A1 · 2018 [cited by applicant]

WO 2018134815A2 · 2018 [cited by applicant]

WO 2018195506A1 · 2018 [cited by applicant]

WO 2019021233A1 · 2019 [cited by applicant]

WO 2019028292A1 · 2019 [cited by applicant]

WO 2019055841A1 · 2019 [cited by applicant]

WO 2019079529A1 · 2019 [cited by applicant]

WO 2019118513A1 · 2019 [cited by applicant]

WO 2020011968A1 · 2020 [cited by applicant]

WO 2020055975A1 · 2020 [cited by applicant]

WO 2020079580A1 · 2020 [cited by applicant]

WO 2020121195A1 · 2020 [cited by applicant]

WO 2020123664A1 · 2020 [cited by applicant]

WO 2020172450A1 · 2020 [cited by applicant]

WO 2020194317A1 · 2020 [cited by applicant]

WO 2021146256A1 · 2021 [cited by applicant]

WO 2021158986A1 · 2021 [cited by applicant]

WO 2021168194A1 · 2021 [cited by applicant]

WO 2022081765A1 · 2022 [cited by applicant]

Cheng et al., “TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function,” J. Biol. Chem., 2018, vol. 293, Issue 32, pp. 12620-126… [cited by applicant]

Database NCBI [Online] Jul. 23, 2016, “immunoglobulin heavy chain variable region, partial [Mus musculus],” GenBank: CAM98769.1, 3 pages. [cited by applicant]

GenBank Accession No. AWK57454.1, mailed May 2018, 2 pages. [cited by applicant]

GenBank Accession No. P01834.2, mailed Mar. 2017, 6 pages. [cited by applicant]

Hsieh et al., “A Role for TREM2 Ligands in the Phagocytosis of Apoptotic Neuronal Cells by Microglia,” J. Neurochem, 2009, 109(4), pp. 1144-1156. [cited by applicant]

Hu et al., “Triggering Receptor Expressed On Myeloid Cells 2 (Trem2) Dependent Microglial Activation Promotes Cisplatin-Induced Peripheral Neuropathy In Mice,” Brain, Behavior and Immunity, vol. 68, 2018, pp. 132-145. [cited by applicant]

International Search Report and Written Opinion received for International Appl. No. PCT/US2020/019093, mailed on Jul. 15, 2020, 28 pages. [cited by applicant]

International Search Report and Written Opinion received for International Appl. No. PCT/US2020/019104, mailed on Jun. 11, 2020, 10 pages. [cited by applicant]

Invitation to Pay Additional Fees, Partial Search Report, and Provisional Opinion for International Appl. No. PCT/US2021/013200, mailed May 7, 2021, 18 pages. [cited by applicant]

Jay et al., “TREM2 in Neurodegenerative Diseases,” Molecular Neurodegeneration, vol. 12, Aug. 2, 2017, pp. 1-33. Available online at https://molecularneurodegeneration.biomedcentral.com/track/pdf/10.1186/s13024-017-0197… [cited by applicant]

Jiang et al., “Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease,” Neuropsychopharmacology, 2014, 39, pp. 2949-2962. [cited by applicant]

Kariolis et al., “Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys,” Sci. Transl. Med., 2020, vol. 12, Issue 545, eaay1359, pp. 1-13. [cited by applicant]

Kobayashi et al., “TREM2/DAP12 Signal Elicits Proinflammatory Response in Microglia and Exacerbates Neuropathic Pain,” The Journal of Neuroscience, vol. 36, No. 43, Oct. 26, 2016, pp. 11138-11150. [cited by applicant]

Kussie et al., “A single engineered amino acid substitution changes antibody fine specificity,” Journal of Immunology, 152(1): 146-152, 1994. [cited by applicant]

Lewcock et al., “Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease,” Neuron, Dec. 9, 2020, 108(5), pp. 801-821. [cited by applicant]

Nugent et al., “TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge,” Neuron, Mar. 4, 2020, 105(5), pp. 1-18. e1-e9. [cited by applicant]

Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proc Natl Acad Sci USA, 85(9):3080-4, May 1988. [cited by applicant]

Piccio et al., “Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis,” Eur. J. Immunol., 2007, 37, pp. 1290-1301. [cited by applicant]

Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Nat. Acad. Sci. USA, vol. 79, pp. 1979-1983, Mar. 1982. [cited by applicant]

Satoh et al., “A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin- embedded postmortem Alzheimer's brain tissues,” Alzheimer's Research & Therapy, vol. 5, No. 4, Article… [cited by applicant]

Schlepckow et al., “Enhancing Protective Microglial Activities with a Dual Function TREM2 Antibody to the Stalk Region,” EMBO Mol Med., Apr. 7, 2020, 12(4):e11227, pp. 1-22. [cited by applicant]

Sudom et al., “Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2,” J. Biol. Chem., 2018, vol. 293, Issue 32, pp. 12634-12646. [cited by applicant]

Sun et al., “TREM-2 Promotes Host Resistance Against Pseudomonas aeruginosa Infection by Suppressing Corneal Inflammation via a PI3K/Akt Signaling Pathway,” Immunology and Microbiology, Invest Ophthalmol Vis Sci, vol. 5… [cited by applicant]

Zhao et al., “A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease,” Sci. Transl. Med., 14:eabq0095, Sep. 7, 2022, 15 pages. [cited by applicant]

Almagro, J. et al., “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy,” Frontiers in Immunology, 8(1751): 1-19, 2018. [cited by applicant]

Dondelinger, M. et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen- Binding Surface/Residue Definition,” Front. Immunol., 9(2278): 1-15, 2018. [cited by applicant]

Frenzel, A. et al., “Chapter 6: Antibody Affinity,” Handbook of Therapeutic Antibodies, Eds S. Dubel and J.M. Reichert, Wiley-VCH Verlag Gmbh & Co., Weinheim, Germany, pp. 115-139, 2014. [cited by applicant]

Gonzales, N. et al., “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumor Biology, 26(1):31-43, 2005. [cited by applicant]

Kunik, V. et al., “Structural consensus among antibodies defines the antigen binding site,” PLOS Comput. Biol., 8(2):e1002388, 2012, 12 pages. [cited by applicant]

Liu, L., “Pharmacokinetics of monoclonal antibodies and FC-fusion proteins,” Protein Cell, 9(1): 15-32, 2018. [cited by applicant]

Lucchese, G. et al., “How a single amino acid change may alter the immunological information of a peptide,” Frontiers in Bioscience, 4(5):1843-52, 2012. [cited by applicant]

Mix, E. et al., “Immunoglobulins-basic considerations,” J. Neurol., 253(Suppl 5): V9-17, 2006. [cited by applicant]

Sela-Culang, I. et al., “The structural basis of antibody-antigen recognition,” Frontiers in Immunology, 4(302):1- 13, 2013. [cited by applicant]

Wark, K. and P. Hudson, “Latest technologies for the enhancement of antibody affinity,” Adv. Drug Deliv. Rev., 58(5-6):657-70, 2006. [cited by applicant]

Wu, H. et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J. Mol. Biol., 294(1): 151-62, 1999. [cited by applicant]